A Phase 2 interventional study of SHR-1826 in Non-Small Cell Lung Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. — 18 open to participants now, 22 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Jiangsu HengRui Medicine Co., Ltd..
Among the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., this one is the 31st largest by planned enrollment, is one of 6 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 14 of the 21 other live ones, and was the 33rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →18 of the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–70
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18–75
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18–75
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 22 · Phase 3 16
First in 2010; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 274 across the 38 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Suzhou Suncadia Biopharmaceuticals Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.
2 of the studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06671379Phase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | 2026-12 |
| NCT05482568Jiangsu HengRui Medicine Co., Ltd.A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-1826
SHR-1826
ORR assessed by IRC according to RECIST v1.1 s)
Time frame: once every 6 weeks, estimated 2 years
Objective Response Rate (ORR) assessed by the investigator according to RECIST v1.1;
Time frame: once every 6 weeks, estimated 2 years
Disease Control Rate (DCR) assessed by the IRC and investigator according to RECIST v1.1;
Time frame: once every 6 weeks, estimated 2 years
Duration of Response (DoR) assessed by the IRC and investigator according to RECIST v1.1;
Time frame: once every 6 weeks, estimated 2 years
Progression-Free Survival (PFS) assessed by the IRC and investigator according to RECIST v1.1;
Time frame: Estimated 2 years
Overall Survival (OS).
Time frame: Estimated 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Aug 2028, 28 months after the start.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 28 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-1826
Carcinoma, Non-Small-Cell Lung →
Suzhou Suncadia Biopharmaceuticals Co., Ltd. →